Preclinical Ophthalmic Drug Development Services ace

Dendrimer Nanoparticle Development Services for Ocular Drug Delivery

Dendrimers have been one of the areas of focus in ocular drug delivery systems in recent years. As a full-scale ocular solution CRO, Ace Therapeutics is committed to providing our customers with one-stop dendrimer ocular delivery system solutions and using them in a variety of research fields, including eye disease gene therapy, glaucoma, neuroinflammatory eye disease, age-related macular degeneration, etc. In addition, our high-quality researchers will also provide corresponding formula development services according to customers' needs, including drops, ointments, gels, and vitreous injections. We look forward to working with you to ensure the success of your project.

Development of a Dendrimer Drug Delivery System for Ocular Disease

Advantages of Dendrimers for Ocular Delivery Systems

Existing ocular drug delivery systems have certain limitations (safety and efficiency). Dendrimers can address this issue by controlling drug biodistribution. It is a synthetic polymer nanoparticle with an unusually highly ordered branched structure. This unique structure provides many useful properties for ocular drug delivery not possessed by many linear polymers. These properties include predictability of distribution, controllability of terminal gene modification, and diversity of drug conjugation modes. In recent years, dendrimers frequently used for ocular delivery have been poly(amidoamine) (PAMAM), PLL, polypropylene imine (PPI), and phosphorous dendrimers. They are mainly used as vectors for gene therapy of ocular diseases, and are an ideal vector for gene therapy of ocular diseases with low toxicity.

Fig. 1. Dendrimer routes of ocular administration. (Lancina MG, et al., 2017)

What Is Ace Therapeutics Doing for Ocular Drug Delivery System Development?

Developing a suitable dendrimer ocular delivery system that can maintain therapeutic drugs and deliver them to target tissues is one of the focuses of Ace Therapeutics' research in recent years. We have a team of experienced experts who can face any key challenges in your project development. Through Ace Therapeutics' experience in developing dendrimer ocular delivery systems, it is possible to provide a customized protocol to advance your project based on the properties of your candidate compounds.

One-stop Dendrimer Drug Delivery System Development Service for Ocular Disease

With more than a decade's experience in the development of ocular delivery systems, Ace Therapeutics provides global customers with one-stop development services for dendrimer drug delivery systems for ocular diseases. Our talented scientists will develop different dendrimer products according to your research area (anterior or posterior segment).

For anterior segment diseases, our expert team adopts topically administered topical preparations. This is done by incorporating them into in situ polymerized gels to improve drug delivery efficiency and bioavailability by prolonging corneal residence time. The administration methods include drops, ointments, gels, etc

For posterior segment diseases, our development strategy is to improve bioavailability by modifying the physicochemical properties of PAMAM dendrimers. This will prolong their vitreous humor residence time. The mode of administration covers vitreous and subconjunctival injection.

Our services include, but are not limited to:

Preparation of dendrimers
Gelation of dendrimers (topical use)
Characterization of dendrimers
In vitro cell evaluation
Corneal permeability assessment (topical use)
Early ocular pharmacodynamic assessment
Ocular irritation assessment
Live animal models of ocular disease

Application Fields

Glaucoma
Neuroinflammatory Ocular Disease
Age-related Macular Degeneration (AMD)
Corneal Wound Healing
Anti-VEGF Therapy
Gene Therapy

Our Capabilities

Additionally, Ace Therapeutics offers the following other ocular delivery systems that may be of interest to you, ask our scientists for details.

As a contract provider of solutions for ocular diseases, in order to better understand unmet needs, successful delivery of ocular drug delivery systems. Ace Therapeutics can provide our customers with one-stop dendrimer ocular delivery system development services. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Lancina MG, Yang H. Dendrimers for Ocular Drug Delivery. Can J Chem. 2017 Sep;95(9):897-902.
Kambhampati SP, Kannan RM. Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther. 2013 Mar;29(2):151-65.

For Research Use Only.

Get in Touch